NASDAQ:BOLD - Audentes Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$25.01 +0.29 (+1.17 %)
(As of 02/20/2019 02:45 AM ET)
Previous Close$24.72
Today's Range$24.79 - $25.66
52-Week Range$17.95 - $46.18
Volume225,200 shs
Average Volume441,455 shs
Market Capitalization$1.07 billion
P/E Ratio-7.36
Dividend YieldN/A
Beta1.79
Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. The company was founded in 2012 and is headquartered in San Francisco, California.

Receive BOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for BOLD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BOLD
CUSIPN/A
Phone415-818-1001

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($5.38) per share

Profitability

Net Income$-90,230,000.00

Miscellaneous

Employees152
Market Cap$1.07 billion
OptionableOptionable

Audentes Therapeutics (NASDAQ:BOLD) Frequently Asked Questions

What is Audentes Therapeutics' stock symbol?

Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."

How were Audentes Therapeutics' earnings last quarter?

Audentes Therapeutics Inc (NASDAQ:BOLD) released its quarterly earnings results on Wednesday, August, 8th. The biotechnology company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.78) by $0.07. View Audentes Therapeutics' Earnings History.

When is Audentes Therapeutics' next earnings date?

Audentes Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Audentes Therapeutics.

What price target have analysts set for BOLD?

11 brokers have issued 12-month target prices for Audentes Therapeutics' shares. Their forecasts range from $20.00 to $49.00. On average, they anticipate Audentes Therapeutics' share price to reach $32.2122 in the next year. This suggests a possible upside of 28.8% from the stock's current price. View Analyst Price Targets for Audentes Therapeutics.

What is the consensus analysts' recommendation for Audentes Therapeutics?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Audentes Therapeutics in the last year. There are currently 1 sell rating, 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Audentes Therapeutics.

What are Wall Street analysts saying about Audentes Therapeutics stock?

Here are some recent quotes from research analysts about Audentes Therapeutics stock:
  • 1. Mizuho analysts commented, "We spoke with management following yesterday’s regulatory update on AT132. Audentes held an encouraging first meeting with regulators and will continue to enroll patients in the high-dose cohort 2. Six-month biopsy data from this high- dose cohort is expected in 2Q19 and will help inform an optimal dose of AT132. Audentes then plans to submit an updated data package to the FDA, after which a second FDA meeting will be held; we anticipate this could happen in 3Q19 and we expect minutes from this meeting will provide more clarity around the pathway to a BLA filing for AT132. This could be an important catalyst in 2019. In the meantime, the next data update will be ASGCT." (2/1/2019)
  • 2. HC Wainwright analysts commented, "Our Buy rating and $33 price target on shares of Audentes are currently leveraged on AT132. We have removed AT342 from our estimates pending clinical clarity anticipated during the company’s 1Q19 call estimated in May 2019. Given the robustness of the clinical data thus far, and the rarity of the condition, we are increasing our AT132 launch price to $1.7M vs. our prior estimate of $1M, which drives AT132 NPV to $33/share, vs. our prior $17/share." (1/11/2019)
  • 3. According to Zacks Investment Research, "Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company's product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia and AT982 for the treatment of pompe disease, which are in pre-clinical trial stage. Audentes Therapeutics, Inc. is based in San Francisco, California. " (1/8/2019)

Has Audentes Therapeutics been receiving favorable news coverage?

Headlines about BOLD stock have trended somewhat negative recently, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Audentes Therapeutics earned a daily sentiment score of -1.0 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days.

Who are some of Audentes Therapeutics' key competitors?

Who are Audentes Therapeutics' key executives?

Audentes Therapeutics' management team includes the folowing people:
  • Mr. Matthew R. Patterson, Co-Founder, Chairman & CEO (Age 46)
  • Ms. Natalie C. Holles, Pres & COO (Age 45)
  • Mr. Thomas P. Soloway, Sr. VP & CFO (Age 51)
  • Dr. John T. Gray, Sr. VP & Chief Scientific Officer (Age 55)
  • Mr. Andrew H. Chang, Director of Investor Relations

When did Audentes Therapeutics IPO?

(BOLD) raised $75 million in an initial public offering (IPO) on Wednesday, July 20th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Audentes Therapeutics' major shareholders?

Audentes Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Partner Fund Management L.P. (7.08%), BlackRock Inc. (6.97%), Orbimed Advisors LLC (4.44%), Great Point Partners LLC (3.88%), Jennison Associates LLC (2.40%) and Victory Capital Management Inc. (2.02%). Company insiders that own Audentes Therapeutics stock include 5Am Partners Iii, Llc, David Nagler, John T Gray, Louis G Lange, Mary Newman, Matthew R Patterson, Orbimed Advisors Llc and Suyash Prasad. View Institutional Ownership Trends for Audentes Therapeutics.

Which institutional investors are selling Audentes Therapeutics stock?

BOLD stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Orbimed Advisors LLC, WS Management Lllp, TD Asset Management Inc., Bank of America Corp DE, Barclays PLC, MetLife Investment Advisors LLC and New York State Common Retirement Fund. Company insiders that have sold Audentes Therapeutics company stock in the last year include David Nagler, John T Gray, Louis G Lange, Mary Newman, Matthew R Patterson, Orbimed Advisors Llc and Suyash Prasad. View Insider Buying and Selling for Audentes Therapeutics.

Which institutional investors are buying Audentes Therapeutics stock?

BOLD stock was acquired by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Partner Fund Management L.P., BB Biotech AG, Millennium Management LLC, BlackRock Inc., Dimensional Fund Advisors LP, Artal Group S.A. and Casdin Capital LLC. View Insider Buying and Selling for Audentes Therapeutics.

How do I buy shares of Audentes Therapeutics?

Shares of BOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Audentes Therapeutics' stock price today?

One share of BOLD stock can currently be purchased for approximately $25.01.

How big of a company is Audentes Therapeutics?

Audentes Therapeutics has a market capitalization of $1.07 billion. The biotechnology company earns $-90,230,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Audentes Therapeutics employs 152 workers across the globe.

What is Audentes Therapeutics' official website?

The official website for Audentes Therapeutics is http://www.audentestx.com.

How can I contact Audentes Therapeutics?

Audentes Therapeutics' mailing address is 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108. The biotechnology company can be reached via phone at 415-818-1001 or via email at [email protected]


MarketBeat Community Rating for Audentes Therapeutics (NASDAQ BOLD)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  258 (Vote Outperform)
Underperform Votes:  229 (Vote Underperform)
Total Votes:  487
MarketBeat's community ratings are surveys of what our community members think about Audentes Therapeutics and other stocks. Vote "Outperform" if you believe BOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BOLD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2019 by MarketBeat.com Staff

Featured Article: Fundamental Analysis

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel